Suppr超能文献

具有透明细胞成分的肺腺癌的突变及临床病理特征分析

Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component.

作者信息

Gu Chang, Pan Xufeng, Wang Rui, Li Yuan, Shen Xuxia, Shi Jianxin, Chen Haiquan

机构信息

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

Oncotarget. 2016 Apr 26;7(17):24596-603. doi: 10.18632/oncotarget.8258.

Abstract

INTRODUCTION

Lung adenocarcinoma with clear cell component is extremely rare and the cases reported in literature remain scarce. The biological behaviors, clinicopathologic characteristics, mutational status and prognosis of lung adenocarcinoma with clear cell component are still uncertain.

METHODS

Thirty-eight lung adenocarcinomas with clear cell component and 1659 lung adenocarcinomas were subjected to the study. All the corresponding clinicopathologic data, the distributions of relapse-free survival (RFS) and overall survival (OS), and the status of gene mutations were investigated.

RESULTS

Of 1697 adenocarcinomas, 38 (2.2%) had clear cell component. Fifty percent of adenocarcinomas with clear cell component (11/22) harbored EGFR mutation, 41 percent (9/22) harbored KRAS mutation and 5 percent (1/22) harbored AKT1 mutation. Univariable analysis revealed that sex, age, tumor stage, tumor size, nodal stage and pathology were all significant predictors of RFS and OS while the tumor size and nodal stage were still significant predictors in multivariable analysis. There were significantly differences in RFS and OS for lung adenocarcinomas with clear cell component compared with those lung adenocarcinomas.

CONCLUSIONS

Lung adenocarcinoma with clear cell component is a rare, malignant tumor with poor prognosis and displays more frequent EGFR and KRAS mutations.

摘要

引言

伴有透明细胞成分的肺腺癌极为罕见,文献报道的病例仍然很少。伴有透明细胞成分的肺腺癌的生物学行为、临床病理特征、突变状态及预后仍不明确。

方法

对38例伴有透明细胞成分的肺腺癌和1659例肺腺癌进行研究。调查所有相应的临床病理数据、无复发生存期(RFS)和总生存期(OS)的分布情况以及基因突变状态。

结果

在1697例腺癌中,38例(2.2%)伴有透明细胞成分。伴有透明细胞成分的腺癌中有50%(11/22)存在表皮生长因子受体(EGFR)突变,41%(9/22)存在Kirsten大鼠肉瘤病毒癌基因(KRAS)突变,5%(1/22)存在蛋白激酶B1(AKT1)突变。单因素分析显示,性别、年龄、肿瘤分期、肿瘤大小、淋巴结分期和病理类型均是RFS和OS的显著预测因素,而在多因素分析中肿瘤大小和淋巴结分期仍是显著预测因素。伴有透明细胞成分的肺腺癌与那些肺腺癌相比,RFS和OS存在显著差异。

结论

伴有透明细胞成分的肺腺癌是一种罕见的恶性肿瘤,预后较差,且EGFR和KRAS突变更为常见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/5029726/fb790f613bb0/oncotarget-07-24596-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验